Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a
reorganization of the company and a significant cost reduction in both early
research and administrative functions. The board has decided that the company
onwards will have an exclusive focus on oncology, utilizing both of Medivir´s
technology platforms and competences in protease inhibition and nucleotide
-/nucleoside science. Partnering discussions for all remaining infectious
disease assets in the R&D pipeline will be initiated by year-end, as well as for
MIV-711 once the phase IIa program has been completed.
The reorganization will result in a total cost reduction of approximately 110
MSEK per year compared to current levels in the affected functions. The
exclusive focus on oncology, along with a reduced number of projects in the
early stage research portfolio, will lead to a reduction of around 25 positions
and cost savings of approximately 60 MSEK vs current spending in the early
stages of development. The reduced early research organization creates
flexibility to strengthen capabilities in clinical development and will enable
broadening the pipeline with oncology projects in clinical phases. At the same
time, efficiency improvements in administrative and commercial support functions
will generate the additional cost savings of approximately 50 MSEK per year
compared to the current levels, impacting around 20 positions.
As a consequence of these changes, a total of around 30 colleagues will
unfortunately have to leave the company and affected vacancies will not be
filled. A redundancy cost of approximately 20 MSEK related to these
organizational changes will be charged in the fourth quarter.
“I believe this reduced cost in early research, and a streamlined therapeutic
area focus with a smaller and more cost effective organization, will strengthen
Medivir´s position as an efficient oncology company with a growing development
pipeline and research platforms for sustainable growth.” says Niklas Prager, CEO
& President of Medivir. He continues: “Medivir´s ambition is to have a well
balanced and broad pipeline from early to late stages of development. We will
continue to build on our technology platforms and proven track record of
translating projects into value creating partnerships.”
For further information, please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 13.00 CET on 10 October 2016.
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.